Night‐to‐night rapid eye movement sleep variability: A relevant marker of early amyloid‐β deposition
Alzheimer's & Dementia · 2026-04 · 22 (4)
DOI: 10.1002/alz.71376 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 17.04.2026. Verfasst von Blandine Montagne und 14 weiteren Autor:innen. Beteiligte Einrichtung: Normandie Univ, UNICAEN, INSERM, UA20, Neuropresage, GIP Cyceron, Caen, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Brain, Sleep Wake Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union's Horizon 2020 Research and Innovation Program, Institut National de la Santé et de la Recherche Médicale, Fondation d'entreprise MMA des Entrepreneurs du Futur.
Abstract (Originalsprache)
INTRODUCTION Sleep disturbances are prevalent in patients with Alzheimer's disease (AD) and may emerge before overt clinical symptoms. We characterized sleep alterations in cognitively unimpaired older adults with cerebral amyloid deposition, and assessed their associations with regional amyloid deposition and cognitive and psychoaffective outcomes. METHODS Seventy‐six older adults (69.1 ± 3.4 years, 63.2% female) underwent a multi‐night (4.5 ± 0.8 nights) objective sleep assessment using the Somno‐Art wearable device, Florbetapir‐positron emission tomography (PET) scanning, and an extensive neuropsychological and psychoaffective evaluation. RESULTS Amyloid β (Aβ)‐positive individuals had a shorter total sleep time (TST) and greater night‐to‐night variability in rapid eye movement (REM) sleep duration than Aβ‐negative individuals. Across the whole sample, these sleep characteristics were associated with increased Aβ deposition in widespread brain regions, but not with cognitive or psychoaffective measures. DISCUSSION Shorter sleep duration and greater REM sleep variability may index early AD‐related brain changes, warranting longitudinal studies to establish their prognostic significance. Trial Registration : Age‐Well randomized clinical trial of the Medit‐Ageing European Project. Trial registration number: EudraCT:2016‐002,441‐36; IDRCB:2016‐A01767‐44; ClinicalTrials.gov Identifier: NCT02977819
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Normandie Univ, UNICAEN, INSERM, UA20, Neuropresage, GIP Cyceron, Caen, France.
- Unité d'Exploration et de Traitement des Troubles du Sommeil, CHU Caen Normandie, Caen, France.
Förderung
- European Union's Horizon 2020 Research and Innovation Program
- Institut National de la Santé et de la Recherche Médicale
- Fondation d'entreprise MMA des Entrepreneurs du Futur
- Région Normandie
Zitieren
APA
Montagne, B., Boulin, M., Hamel, A., Champetier, P., Rehel, S., Mézenge, F., Landeau, B., Delarue, M., Hébert, O., Soussi, C., Bertran, F., Chételat, G., André, C., Rauchs, G., & Medit‐Ageing Research Group (2026). Night‐to‐night rapid eye movement sleep variability: A relevant marker of early amyloid‐β deposition. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71376
Vancouver
Montagne B, Boulin M, Hamel A, Champetier P, Rehel S, Mézenge F, et al. Night‐to‐night rapid eye movement sleep variability: A relevant marker of early amyloid‐β deposition. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71376
BibTeX
@article{Montagne2026,
author = {Montagne, Blandine and Boulin, Maéva and Hamel, Anaïs and Champetier, Pierre and Rehel, Stéphane and Mézenge, Florence and Landeau, Brigitte and Delarue, Marion and Hébert, Oriane and Soussi, Célia and Bertran, Françoise and Chételat, Gaël and André, Claire and Rauchs, Géraldine and Medit‐Ageing Research Group, Medit‐Ageing Research Group},
title = {Night‐to‐night rapid eye movement sleep variability: A relevant marker of early amyloid‐β deposition},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {4},
doi = {10.1002/alz.71376}
}
EUVIMED